In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients

Chemotherapy

Volumn 57, Issue 6, 2012, Pages 505-510

  Bozkurt Guzel, Cagla ^a   Savage, Paul B ^b   Gerceker, Ayse Alev ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Brigham Young University   (United States)

Author keywords

Colistin; Combination; CSA 13; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; CERAGENIN CSA 13; CIPROFLOXACIN; COLISTIN; STEROID; TOBRAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BROTH DILUTION; COMPARATIVE STUDY; CYSTIC FIBROSIS; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

CIPROFLOXACIN; COLISTIN; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STEROIDS; TOBRAMYCIN;

EID: 84856203441     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000335588     Document Type: Article

References (24)

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080. (Pubitemid 19231815)
2. Miller MB, Gilligan PH: Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003; 41: 4009-4015. (Pubitemid 37099657)
3. Savage PB, Li C, Taotafa U, Ding B, Guan Q: Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002; 217: 1-7. (Pubitemid 35356536)
4. Hadley EB, Hancock RE: Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr Top Med Chem 2010; 8: 1872-1881.
5. Lai XZ, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, Epand RF, Epand RM, Savage PB: Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res 2008; 41: 1233-1240.
6. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ: Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365-370.
7. Chin JN, Rybak MJ, Cheung CM, Savage PB: Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 1268-1273. (Pubitemid 46586804)
8. Isogai E, Isogai H, Takahashi K, Okumura K, Savage PB: Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria. Oral Microbiol Immunol 2009; 24: 170-172.
9. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K: Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25. (Pubitemid 40023341)
10. Falagas ME, Kasiakou SK: Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27.
11. Kunz AN, Brook I: Emerging resistant Gram-negative aerobic bacilli in hospitalacquired infections. Chemotherapy 2010; 56: 492-500.
12. Bozkurt-Guzel C, Gerceker AA: In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy 2008; 54: 147-151. (Pubitemid 351448602)
13. Ozbek B, Senturk A: Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemotherapy 2010; 56: 466-471.
14. Guan Q, Li C, Schmidt EJ: Preparation and characterization of cholic acid-derived antimicrobial agents with controlled stabilities. Org Lett 2000; 2: 2837-2840.
15. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A7, ed 7. Wayne, CLSI, 2006.
16. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement -M100-S20. Wayne, CLSI, 2010.
17. National Committee for Clinical Laboratory Standards: Methods for Determining Bactericidal Activity of Antimicrobial Agents -Approved Guideline M26-A. Wayne, NCCLS, 1999.
18. Pillai SK, Moellering RC Jr, Eliopoulos GM: Antimicrobial Combinations; in Lorian V (ed): Antibiotics in Laboratory Medicine. Philadelphia, Lippincott Williams and Wilkins, 2005, pp 365-440.
19. Odds FC: Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1. (Pubitemid 36850074)
20. Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM: Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother 2010; 54: 3708-3713.
21. Doring G, Conway SP, Heijerman HG, Hudson ME, Hoiby N, Smyth A, Touw DJ: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
22. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH: Nebulised colomycin for early pseudomonal colonisation in cystic fibrosis. Lancet 1985; 1: 865. (Pubitemid 15115129)
23. Ratjen F, Doring G, Nikolaizik WH: Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-984. (Pubitemid 32913526)
24. Taccetti G, Campana S, Festini F, Mascherini M, Doring G: Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 1-4.